Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New PNH pill shows promise in Head-to-Head trial

NCT ID NCT06799546

First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 27 times

Summary

This study tested a new pill called HSK39297 against a standard infusion drug (eculizumab) in 73 adults with PNH, a rare blood disorder. The goal was to see if the pill could raise hemoglobin levels and reduce the need for blood transfusions. Participants had not received prior complement inhibitor therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210029, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310003, China

Conditions

Explore the condition pages connected to this study.